Apogenix signs licensing contract with CANbridge to commercialize APG101 in China.

Apogenix signs licensing contract with CANbridge to commercialize APG101 in China, Macao and Hong Kong Apogenix, a next generation immuno-oncology company, announced today that it offers entered into a special licensing agreement with CANbridge Lifestyle Sciences, a biopharmaceutical company centered on developing Western drug candidates in North and China Asia, for the commercialization and development of lead immuno-oncology drug applicant APG101 in China, Macao, and Hong Kong. Beneath the conditions of the contract, Apogenix will receive upfront and milestone payments, in addition to royalty payments at tiered, double-digit royalty rates following commercial launch of APG101 in China http://www.propeciasverige.com/ .

baldness type

Leerink and Citigroup Swann are performing as joint book-running managers for the providing. Lazard Capital Markets, RBC Capital Marketplaces and Oppenheimer & Co. Are acting as co-managers. ArQule provides granted the underwriters a 30-day time option to purchase up to an additional 1,072,500 shares of common stock. The expected net proceeds to ArQule referenced above do not consist of any net proceeds that ArQule would receive if the underwriters exercise such substitute for purchase additional shares.. ArQule prices underwritten public offering of 7,150,000 shares of common stock ArQule, Inc. today announced the pricing of an underwritten general public offering of 7,150,000 shares of its common stock at a cost of $7.30 per share. The web proceeds to ArQule from the sale of the shares, after deducting underwriting discounts and commissions and estimated expenses, are anticipated to be approximately $48.7 million.